Gut Microbiome: A New Mechanism to Monitor Response to Biologics?
The gut microbiome is complex within irritable bowel disease (IBD), and its disruption may be a potential contributing factor in the pathogenesis of IBD.
The gut microbiome is complex within irritable bowel disease (IBD), and its disruption may be a potential contributing factor in the pathogenesis of IBD.
Dysbiosis of the gut microbiota was identified in individuals with cardiovascular disease and modeled using machine learning.
Treatments guided by metagenomics may result in symptom improvement for patients with irritable bowel syndrome.
It is unclear if alterations in the intestinal microbiota cause celiac disease, or if the changes are a result of celiac disease.
This study assessed the contribution of the proximal small intestinal microbiota to stunting in an undernourished pediatric population who did not respond to nutritional intervention.
Although further study is required, pilot study results suggest that FMT may be a viable option for patients with IBS with significant bloating.
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.
The microbiota-gut-brain axis represents a bidirectional communication pathway through which the gut microbiota may influence the CNS.
Pre/probiotic therapy may be useful for patients with depression and/or anxiety disorders.
Examining the gut microbiome for biomarkers that may aid in the detection of pre-cancerous adenomas and/or CRC has significant utility in both research and real world settings.